Le Lézard
Classified in: Health, Science and technology
Subject: PDT

CEM Introduces the Future of Molecular Sample Preparation


MATTHEWS, N.C., Oct. 17, 2017 /PRNewswire/ -- CEM Corporation, a leading supplier of sample preparation systems, is pleased to introduce the all new EDGEtm extraction system for rapid sample preparation of GC/LC samples.  Featuring advanced Q-Cuptm Technology, the EDGEtm can prepare samples for molecular analysis in as little as 5 minutes with exceptional recovery and repeatability.

EDGE Rapid Sample Prep for LC/GC

"The EDGEtm is a simple solution to a complicated problem," commented Michael J. Collins, President and CEO of CEM Corporation.  "It is estimated that 75% of all time spent on chromatographic analysis is in sample preparation.  We have developed a system with incredible performance that will reduce sample preparation time from hours to minutes.  EDGEtm will radically change how laboratories prepare samples for GC and LC analysis."

The new EDGEtm technology is based on energized, dispersive, guided, extraction and combines traditional pressurized fluid extraction with dSPE.  The system is covered by multiple pending patent applications.  This new automated process provides flexibility and speed never before achieved. The EDGEtm is a complete solution to sample preparation providing fluid addition, rapid extraction, sample filtration, and fluid dispensing all in less than 5 minutes.  Also, with the addition of appropriate Q-sorbentstm it can combine analyte extraction and sample cleanup in a rapid single step process.

The EDGEtm is compact (about the size of an analytical balance) and can process 12 samples per hour. This allows high throughput labs to use multiple units to process 50 - 100 samples per hour. Key markets are environmental, food, plastics, consumer products, pharmaceuticals, forensics and clinical.

CEM is a science based technology company passionate about simplifying science.  Collins said "CEM's passion is to disrupt markets with new solutions that provide speed and simplicity...we make things faster, simpler and smaller.  We believe the EDGEtm technology is truly a breakthrough technology that will completely transform the world of sample preparation in the next few years."

CEM Corporation, a private company based in Matthews, North Carolina, is a leading provider of laboratory instrumentation. The Company has subsidiaries in the United Kingdom, Germany, Italy, France, and Japan, as well as a global network of distributors. CEM designs and manufactures systems for life sciences, analytical laboratories and processing plants worldwide. The Company's products are used in many industries including pharmaceutical, biotech, chemical and food processing, as well as academic research.

CEM Corporation logo. (PRNewsFoto/CEM Corporation)

SOURCE CEM Corporation


These press releases may also interest you

at 17:00
StateHouse Holdings Inc. ("StateHouse" or the "Company") , a California-focused, vertically integrated cannabis company, today announced further to its press release dated April 15, 2024, that the Ontario Securities Commission (the "OSC") has denied...

at 16:42
Grifols, S.A. ("Grifols") (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announces the filing of its Annual Report on Form 20-F for the fiscal year ended December 31,...

at 16:27
Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Thursday, the FDA posted a safety communication to inform the public and healthcare providers that the agency has required and...

at 16:19
Unifor expects to achieve the wage increases and benefit improvements awarded to Ontario OCHU-CUPE and SEIU Healthcare members by Arbitrator William Kaplan in a recent decision....

at 16:10
Acadia Pharmaceuticals Inc. today announced that on April 10, 2024, the Compensation Committee of Acadia's Board of Directors (the "Committee") granted inducement awards consisting of non-qualified stock options to purchase 21,659 shares of common...

at 16:10
Calidi Biotherapeutics, Inc. , a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the closing of its previously announced public offering of 15,197,500 shares of common stock (or pre-funded...



News published on and distributed by: